Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast cancer

Breast Care

Volumn 5, Issue SUPPL. 1, 2010, Pages 13-15

  Bauerfeind, Ingo ^a   Elling, Dirk ^b   Heinemann, Volker ^c  

^a Klinikum Landshut   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

EGF30008 trial; Endocrine resistance; ErbB2 positive breast cancer; ErbB2 ER pathway crosstalk; Hormone receptors

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CONTROL; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG TREATMENT FAILURE; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RASH; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 77952826677     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000285775     Document Type: Short Survey

References (14)

1. Prat A, Baselga J: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008;5:531-542.
2. Carlson RW, Allred DC, Anderson BO, Burstein HJ, et al.: Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7: 122-192.
3. Kreienberg R , Kopp I, Albert U, et al.: Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Deutsche Krebsgesellschaft e.V. (DKG) und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) 1. Aktualisierung 2008.
4. Arpino G, Weichmann L, Osborne CK, et al: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev 2008; 29:217-233.
5. Ellis MJ, Coop A, et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
6. Johnston S, Dowsett M: Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-831. (Pubitemid 37376980)
7. Osborne CK, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-1622.
8. Massarweh S, Osbonre K, Joang S, et al.: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006;66:8266-8273.
9. Chu I, Blackwell K, Chen S, Slingerland J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
10. Leary AF, Martin LA, Lykkesfeldt AE, Dowsett M, Johnston SRD: Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in cell models of endocrine resistance. Breast Cancer Res Treat 2006; 100(suppl): S29, abstr 303.
11. Johnston S, Pippen J Jr, Pivot X, et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
12. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
13. Marty M, Cognetti F, Maraninchi D, et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
14. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.